FGF21 and the second coming of PPARγ.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22304910.
- Also identified by DOI 10.1016/j.cell.2012.01.020 and PMC identifier 3357185.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Peptide hormone fibroblast growth factor-21 (FGF21) has insulin-mimetic properties. Dutchak et al. now suggest that FGF21 also acts in an autocrine fashion in adipocytes and is required to mediate effects of the PPARγ agonist class of antidiabetic drugs. Does this new property improve FGF21's fledgling clinical prospects or endorse a clinical resuscitation of PPARγ agonists?